Adding the investigational therapy selinexor to an approved regimen of Jakafi (ruxolitinib) in the Phase 3 SENTRY trial led to a greater reduction in spleen size and may have improved survival for participants with myelofibrosis, according to selinexor’s developer, Menarini Group. “The strength of the spleen…
News
An elderly woman with primary myelofibrosis experienced disease worsening despite being on treatment with hydroxyurea and was later found to have a rare mutation in the CALR gene that had been missed by routine genetic testing. According to clinicians, the woman’s “clinical progression prompted repeat [blood] and molecular evaluation,” with…
Circulating myeloblasts (CMB), a type of immature white blood cell commonly found in the bloodstream of people with myelofibrosis, may serve as a marker of disease severity and outcomes, according to a pilot study. Blood levels of myeloblasts, measured by a sensitive technique called flow cytometry, correlated with established…
Treatment with DISC-0974, Disc Medicine’s experimental antibody therapy for myelofibrosis-associated anemia, led to durable anemia responses across patient subgroups and clinically significant fatigue improvements in certain groups of people with myelofibrosis, according to updated Phase 2 trial data. The Phase 1b/2 clinical trial, called RALLY-MF (NCT05320198), is…
Cero Therapeutics is expanding enrollment in an early clinical trial that’s testing its T-cell-based therapy candidate CER-1236, to now include people with hard-to-treat myelofibrosis. The Phase 1/1b CERTAIN-T study (NCT06834282) is a first-in-human, open-label trial — meaning both participants and investigators know the treatment being given to…
Treatment with Vonjo (pacritinib) before a stem cell transplant safely eased symptoms and spleen enlargement in people with myelofibrosis, while also allowing most patients to undergo their planned procedure, according to final findings from a Phase 2 trial. The findings support Vonjo as a “feasible and effective symptomatic treatment” for…
Eli Lilly is acquiring Ajax Therapeutics to advance AJ1-11095, an experimental next-generation JAK2 inhibitor designed to deliver deeper, longer-lasting benefits for patients with myelofibrosis and other blood cancers that do not respond well to existing treatments. “Lilly has long believed in the approach and is excited…
The U.S. Food and Drug Administration (FDA) has approved a new once-daily formulation of Jakafi (ruxolitinib), known as Jakafi XR, for adults with intermediate- or high-risk myelofibrosis. Like the original version of Jakafi, which is taken twice daily, Jakafi XR is also FDA-approved to treat certain people…
People with myelofibrosis who had low blood cell counts before starting ruxolitinib had shorter overall survival after treatment, according to a new study. “Cytopenias [low blood cell counts] before the start of ruxolitinib treatment have an unfavorable effect on the outcome and survival of patients with myelofibrosis,” researchers wrote in…
Combining the blood cancer therapy selinexor with Jakafi (ruxolitinib), an oral treatment approved for adults with myelofibrosis, outperformed Jakafi alone in rapidly reducing spleen size and showed promising signs of extending survival. These are the early findings from Karyopharm Therapeutics‘ ongoing global Phase 3 trial, dubbed SENTRY (NCT04562389),…
Recent Posts
- MPN Awareness Day puts focus on myelofibrosis, other rare blood cancers
- Talking about MF’s effects can be a gift to friends and loved ones
- FDA accelerated approval sought for myelofibrosis combo therapy
- Seeking out the joy to be found in the simplest of things
- Damora launches trial testing novel antibody therapy for rare blood cancers